Boston-based ORIG3N, Inc., a biomedical research company, has closed a $20 million funding round involving South Korea’s KTB-KORUS Fund, which is managed by KTB Ventures.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
